Literature DB >> 16132904

Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus.

Argiris Symeonidis1, Alexandra Kouraklis-Symeonidis, Agathoklis Psiroyiannis, Michalis Leotsinidis, Venetsana Kyriazopoulou, Pavlos Vassilakos, Apostolos Vagenakis, Nicholas Zoumbos.   

Abstract

We investigated erythropoietin (Epo) response in a cohort of diabetic patients with various types of anemia to approach the pathogenesis of some cases of "unexplained" anemia encountered among diabetics. Serum Epo levels were determined totally in 747 evaluable subjects with normal renal and hepatic function, of whom 694 had anemia. Among anemic patients, 237 were diabetics, while among the 53 nonanemic persons, there were also 21 diabetics. Diabetic and nondiabetic subjects were uniformly balanced in relation to their demographic features and were categorized according to the etiology of their anemia. Hemoglobin (Hb) did not differ between diabetic and nondiabetic subjects in all the etiological groups and in the whole population. Diabetic patients had significantly lower serum Epo levels as compared to nondiabetics (36.5+/-61 vs 69.4+/-191 IU/ml, p<0.0001), and this was true for all etiologic groups of anemia with the exception of patients with myeloproliferative disorders and those with megaloblastic anemia. The natural logarithmic (ln)-EpoxHb component was used as an index of response to anemia and was found to be significantly decreased in almost all subgroups of diabetic patients. Serum Epo levels were also negatively correlated with the percentage of glycosylated Hb, HbA1(C) (r=-0.446), and the correlation was stronger with the ln of serum Epo (r=-0.638, p<0.001). Inappropriately low serum Epo level is a uniform feature in patients with type II diabetes mellitus and may represent a constitutive blunted response to anemia or an altered metabolic rate of Epo, probably as a result of abnormal glycosylation of the cytokine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16132904     DOI: 10.1007/s00277-005-1102-9

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  24 in total

1.  Diabetic stress: new triumphs and challenges to maintain vascular longevity.

Authors:  Kenneth Maiese
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-03

Review 2.  Erythropoietin and diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  World J Diabetes       Date:  2015-10-25

3.  EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3β, and β-catenin to foster vascular integrity during experimental diabetes.

Authors:  Zhao Zhong Chong; Jinling Hou; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2011-05       Impact factor: 1.990

Review 4.  Not so benign haematology: anaemia of the elderly.

Authors:  Akil A Merchant; Cindy N Roy
Journal:  Br J Haematol       Date:  2011-11-03       Impact factor: 6.998

Review 5.  Novel avenues of drug discovery and biomarkers for diabetes mellitus.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  J Clin Pharmacol       Date:  2010-03-10       Impact factor: 3.126

Review 6.  Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  Biomed Pharmacother       Date:  2008-02-20       Impact factor: 6.529

Review 7.  Erythropoietic stress and anemia in diabetes mellitus.

Authors:  Dhruv K Singh; Peter Winocour; Ken Farrington
Journal:  Nat Rev Endocrinol       Date:  2009-04       Impact factor: 43.330

8.  High association of IL-4 gene intron 3 VNTR polymorphism with diabetic peripheral neuropathy.

Authors:  Nursah Basol; Ahmet Inanir; Serbulent Yigit; Nevin Karakus; Suheyla Uzun Kaya
Journal:  J Mol Neurosci       Date:  2013-06-16       Impact factor: 3.444

Review 9.  Erythropoietin and oxidative stress.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Curr Neurovasc Res       Date:  2008-05       Impact factor: 1.990

Review 10.  Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  ScientificWorldJournal       Date:  2009-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.